PRNewsWire
23 Jul 2026, 10:45 UTC · 8w ago
Verdict
Headline leans bullish. We score DGX +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Quest Diagnostics raised its full-year 2026 guidance for net revenues, reported diluted EPS, and adjusted diluted EPS.
More positive than 98% of claims this week
The company reported a 19.1% year-over-year increase in adjusted diluted EPS for the second quarter of 2026.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 91% of claims this week
Net revenues increased by 10.2% in Q2 2026, driven primarily by 13.1% growth in requisition volume.
More positive than 84% of claims this week
Revenue per requisition declined by 2.8% in the second quarter compared to the previous year.
So whatPricing pressure or a shift in test mix suggests a potential headwind to margins despite volume growth.
More negative than 73% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported robust top- and bottom-line growth, including a 10.2% increase in net revenues and raised its full-year revenue and EPS guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1d ago
+17.5%
Price agrees with the score
$246.48 vs $209.83 close before publication (Jul 22) · not market-adjusted
DGX chart →
